Clinical factors associated with treatment outcomes in EGFR mutant non-small cell lung cancer patients with brain metastases: a case-control observational study
Background Non-small cell lung cancer (NSCLC) patients harboring epidermal growth factor
receptor (EGFR) mutations often develop brain metastases. Treatment with EGFR-tyrosine …
receptor (EGFR) mutations often develop brain metastases. Treatment with EGFR-tyrosine …
Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC
JS Ju, ACC Huang, PH Tung, CH Huang, TH Chiu… - Scientific Reports, 2023 - nature.com
Non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutation
is brain metastasis (BM)-prone. We determined the impact of this hallmark, along with EGFR …
is brain metastasis (BM)-prone. We determined the impact of this hallmark, along with EGFR …
Survival of patients with brain metastases from non-small cell lung cancer harboring EGFR mutations treated with epidermal growth factor receptor tyrosine kinase …
J Kashima, Y Okuma, M Miwa, Y Hosomi - Medical Oncology, 2016 - Springer
Brain metastases (BM) is one of the most crucial distant metastases in patients with non-
small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) …
small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) …
Comparison of the efficacies of first-generation epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in patients with advanced non-small-cell …
N Aiko, T Shimokawa, K Miyazaki, Y Misumi, Y Agemi… - BMC cancer, 2018 - Springer
Background Compared with standard chemotherapy, epidermal growth factor receptor
tyrosine kinase inhibitors (EGFR-TKIs) are more effective in patients with advanced non …
tyrosine kinase inhibitors (EGFR-TKIs) are more effective in patients with advanced non …
Effects of epidermal growth factor receptor‐tyrosine kinase inhibitors alone on EGFR‐mutant non‐small cell lung cancer with brain metastasis
Q Zhang, X Zhang, H Yan, B Jiang, C Xu… - Thoracic …, 2016 - Wiley Online Library
Background Epidermal growth factor receptor‐tyrosine kinase inhibitors (EGFR‐TKI s) are
remarkably effective for treating EGFR‐mutant non‐small cell lung cancer (NSCLC) …
remarkably effective for treating EGFR‐mutant non‐small cell lung cancer (NSCLC) …
The effectiveness of EGFR-TKIs against brain metastases in EGFR mutation-positive non-small-cell lung cancer
H Bai, B Han - OncoTargets and therapy, 2017 - Taylor & Francis
Brain metastases are usual in non-small-cell lung cancer (NSCLC) with poor prognosis and
few available therapeutic options. This retrospective study aims to evaluate the efficacy of …
few available therapeutic options. This retrospective study aims to evaluate the efficacy of …
Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 …
SJ Park, HT Kim, DH Lee, KP Kim, SW Kim, C Suh… - Lung cancer, 2012 - Elsevier
Non-small cell lung cancer (NSCLC) harboring an activating epidermal growth factor
receptor (EGFR) mutation shows good and rapid response to EGFR tyrosine kinase …
receptor (EGFR) mutation shows good and rapid response to EGFR tyrosine kinase …
Impacts of EGFR mutation and EGFR-TKIs on incidence of brain metastases in advanced non-squamous NSCLC
BX Wang, W Ou, XY Mao, Z Liu, HQ Wu… - Clinical Neurology and …, 2017 - Elsevier
Objective Brain metastases remain lethal in lung cancer patients. The impacts of epidermal
growth factor receptor (EGFR) mutations and EGFR tyrosine kinase inhibitors (TKIs) on the …
growth factor receptor (EGFR) mutations and EGFR tyrosine kinase inhibitors (TKIs) on the …
[HTML][HTML] The different central nervous system efficacy among gefitinib, erlotinib and afatinib in patients with epidermal growth factor receptor mutation-positive non …
HA Jung, SY Woo, SH Lee, JS Ahn… - Translational Lung …, 2020 - ncbi.nlm.nih.gov
Background Brain metastasis is common in non-small cell lung cancer (NSCLC) and has an
even higher incidence in epidermal growth factor receptor (EGFR)-mutant cancers. Although …
even higher incidence in epidermal growth factor receptor (EGFR)-mutant cancers. Although …
EGFR mutation status and its impact on survival of Chinese non-small cell lung cancer patients with brain metastases
D Luo, X Ye, Z Hu, K Peng, Y Song, X Yin, G Zhu, Q Ji… - Tumor Biology, 2014 - Springer
Brain metastasis (BM) is a leading cause of death in patients with non-small cell lung cancer
(NSCLC). EGFR mutations in primary NSCLC lesions have been associated with sensitivity …
(NSCLC). EGFR mutations in primary NSCLC lesions have been associated with sensitivity …
相关搜索
- clinical factors brain metastases
- lung cancer brain metastases
- treatment outcomes brain metastases
- treatment outcome egfr tki
- treatment outcomes clinical factors
- egfr mutation brain metastases
- lung cancer growth factor
- survival of patients brain metastases
- lung cancer egfr mutations
- neurological death brain metastases
- lung cancer comparison of the efficacies
- egfr mutations growth factor
- receptor tyrosine growth factor
- kinase inhibitors growth factor
- receptor tyrosine kinase inhibitors
- survival of patients egfr mutations